Success Metrics

Clinical Success Rate
50.0%

Based on 6 completed trials

Completion Rate
50%(6/12)
Active Trials
3(20%)
Results Posted
133%(8 trials)
Terminated
6(40%)

Phase Distribution

Ph phase_1
4
27%
Ph phase_2
8
53%
Ph phase_3
3
20%

Phase Distribution

4

Early Stage

8

Mid Stage

3

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
4(26.7%)
Phase 2Efficacy & side effects
8(53.3%)
Phase 3Large-scale testing
3(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

6 of 12 finished

Non-Completion Rate

50.0%

6 ended early

Currently Active

3

trials recruiting

Total Trials

15

all time

Status Distribution
Active(3)
Completed(6)
Terminated(6)

Detailed Status

Completed6
Terminated6
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
3
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (26.7%)
Phase 28 (53.3%)
Phase 33 (20.0%)

Trials by Status

recruiting17%
active_not_recruiting213%
completed640%
terminated640%

Recent Activity

3 active trials
Showing 5 of 15
recruitingphase_3

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

NCT07621809
completedphase_3

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05350072
active_not_recruitingphase_3

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214
completedphase_2

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

NCT03656562
terminatedphase_1

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

NCT04903197
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07621809Phase 3

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

Recruiting
NCT05350072Phase 3

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Completed
NCT05349214Phase 3

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active Not Recruiting
NCT03656562Phase 2

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Completed
NCT04903197Phase 1

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Terminated
NCT03217422Phase 2

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Completed
NCT03827798Phase 2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active Not Recruiting
NCT03400176Phase 1

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Terminated
NCT02962895Phase 2

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Completed
NCT03287414Phase 2

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Terminated
NCT01930175Phase 2

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

Terminated
NCT02149420Phase 2

PD of VAY736 in Patients With Primary Sjögren's Syndrome

Completed
NCT02038049Phase 2

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

Terminated
NCT02675803Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

Completed
NCT02137889Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Terminated

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15